Business Description
Thor Medical ASA
ISIN : NO0010597883
Total Employee Number:
18Description
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.05 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.38 | |||||
Debt-to-EBITDA | -4.2 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 59.9 | |||||
3-Year FCF Growth Rate | 53.1 | |||||
3-Year Book Growth Rate | 33.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.69 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 674.08 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.43 | |||||
9-Day RSI | 52.08 | |||||
14-Day RSI | 49.62 | |||||
3-1 Month Momentum % | -19.54 | |||||
6-1 Month Momentum % | -15.46 | |||||
12-1 Month Momentum % | 78.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.57 | |||||
Quick Ratio | 4.5 | |||||
Cash Ratio | 4.11 | |||||
Days Sales Outstanding | 144.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.8 | |||||
Shareholder Yield % | -16.92 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -13920 | |||||
Net Margin % | -11600 | |||||
EBITDA Margin % | -8160 | |||||
FCF Margin % | -23953.49 | |||||
OCF Margin % | -9467.44 | |||||
ROE % | -13.74 | |||||
ROA % | -10.33 | |||||
ROIC % | -17.01 | |||||
ROC (Joel Greenblatt) % | -65.05 | |||||
ROCE % | -11.65 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4519.95 | |||||
PB Ratio | 3.51 | |||||
Price-to-Tangible-Book | 7.63 | |||||
EV-to-EBIT | -24.96 | |||||
EV-to-EBITDA | -37.75 | |||||
EV-to-Revenue | 3080.2 | |||||
EV-to-FCF | -13.2 | |||||
Earnings Yield (Greenblatt) % | -4.01 | |||||
FCF Yield % | -7.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Thor Medical ASA Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.043 | ||
| EPS (TTM) (€) | -0.016 | ||
| Beta | -0.991 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.71 | ||
| Volatility % | 51.69 | ||
| 14-Day RSI | 49.62 | ||
| 14-Day ATR (€) | 0.007779 | ||
| 20-Day SMA (€) | 0.373325 | ||
| 12-1 Month Momentum % | 78.35 | ||
| 52-Week Range (€) | 0.1934 - 0.506 | ||
| Shares Outstanding (Mil) | 360 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thor Medical ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thor Medical ASA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-28 | In 50 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 50 days | ||
| General meeting for 2026 | 2026-04-23 14:00 | 0.46 (+0.00%) | ||
| Annual report for 2025 | 2026-03-27 08:00 | 0.41 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:00 | 0.40 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 07:00 | 0.40 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-29 08:00 | 0.24 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 07:00 | 0.24 (+0.00%) | ||
| General meeting for 2025 | 2025-04-24 14:00 | 0.20 (+0.00%) | ||
| Annual report for 2024 | 2025-03-28 07:00 | 0.22 (+0.00%) |
Show
Entries
Thor Medical ASA Frequently Asked Questions
What is Thor Medical ASA(FRA:8NN)'s stock price today?
The current price of FRA:8NN is €0.38. The 52 week high of FRA:8NN is €0.51 and 52 week low is €0.19.
When is next earnings date of Thor Medical ASA(FRA:8NN)?
The next earnings date of Thor Medical ASA(FRA:8NN) is 2026-08-28.
Does Thor Medical ASA(FRA:8NN) pay dividends? If so, how much?
Thor Medical ASA(FRA:8NN) does not pay dividend.
Press Release
Articles on Thor Medical ASA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers